Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity

Progress in Neuro-psychopharmacology & Biological Psychiatry
Tuba OzcanliAbdullah Sonsuz

Abstract

Atypical antipsychotics commonly cause isolated asymptomatic increase in the aminotransferase levels. Among these atypical antipsychotics, mostly transient, asymptomatic increase in hepatic enzymes has been reported with olanzapine, however olanzapine rarely may induce a clinical and/or biological hepatic toxicity. The pathogenesis of olanzapine-associated hepatotoxicity is not well known and is mostly a transient phenomenon. However, substantial and lasting changes may occur and result in symptomatic hepatitis. In the following case report, we report on a 44-year-old female patient diagnosed as Bipolar Disorder Type I, whose liver enzyme levels increased ten fold of normal ranges during the third year of the olanzapine treatment and returned to the normal levels within three weeks after olanzapine discontinuation. Although significant liver enzyme elevations are uncommon during olanzapine treatment, based on reports of serious hepatotoxicity, controlled and longitudinal research are needed to learn side effects of this drug on liver. Clinicians should be aware of possible hepatotoxic effects of atypical antipsychotics and should monitor the liver enzyme levels whenever they feel necessary.

References

May 1, 1997·Journal of the American Academy of Child and Adolescent Psychiatry·S KumraD Grothe
Aug 1, 1997·Journal of Clinical Psychopharmacology·M HummerW W Fleischhacker
Apr 27, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K Selim, N Kaplowitz
Aug 26, 1999·Journal of Child and Adolescent Psychopharmacology·E SzigethyR L Findling
Feb 24, 2001·The American Journal of the Medical Sciences·A RazT Hayek
Feb 15, 2003·Annals of Internal Medicine·Khaled A JadallahAnthony M Colatrella
Jul 2, 2003·Tropical Gastroenterology : Official Journal of the Digestive Diseases Foundation·Y Chawla, Deepak Amrapurkar
Oct 16, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Joseph Gonzalez-HeydrichEnrico Mezzacappa
Nov 13, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·George GaryfallosKostas Fokas
Jul 10, 2004·International Journal of Psychiatry in Medicine·Ayten ErdoganHakan Senturk
Nov 25, 2004·Best Practice & Research. Clinical Gastroenterology·Helena Cortez-Pinto, Maria Ermelinda Camilo
Jun 14, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Antonio CiudadEnrique Alvarez
Jan 1, 2004·International Journal of Psychiatry in Clinical Practice·Eleonora Tchernichovsky, Pinkhas Sirota

❮ Previous
Next ❯

Citations

Oct 22, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·Zekai HaliciBunyami Unal
Nov 6, 2009·Advances in Therapy·Coleman GrossJoseph K Belanoff
Dec 1, 2009·The Psychiatric Clinics of North America·Delmar D ShortMaureen F McCarthy
Sep 22, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Chung-Chieh HungChih-Chia Huang
Feb 9, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ayten ErdoganIbrahim Balcioglu
Jun 30, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Nuray AtasoyYucel Ustundag
Oct 18, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Nevena TodorovićDragana Filipović
Mar 31, 2015·Proteomics. Clinical Applications·Julian A JarosSabine Bahn
Dec 3, 2014·British Journal of Clinical Pharmacology·Antonios DourosEdeltraut Garbe
Apr 18, 2014·Journal of Pharmacological Sciences·Ling-ling JiaXiao-dong Liu
Nov 11, 2016·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Rehmat ShahKhwaja Fawad
Jul 28, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Mahmoud SlimRaul J Andrade
Sep 18, 2016·General Hospital Psychiatry·Jer-Hwa HsuChing-Heng Lin
Sep 23, 2011·Toxicology and Industrial Health·Basak TogarEbubekir Dirican
Jun 15, 2010·Toxicology and Industrial Health·Hasan Türkez, Başak Toğar
Feb 22, 2017·World Journal of Gastrointestinal Pharmacology and Therapeutics·Diogo Telles-CorreiaSérgio Machado
Apr 7, 2007·Current Opinion in Gastroenterology·Cherinne Arundel, James H Lewis
Jan 15, 2019·Journal of Clinical Psychopharmacology·Nicola DusiAntonio Lasalvia
Jun 18, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Chantal SchlatterStephan Krähenbühl
Sep 8, 2020·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Katrin DruschkyDetlef Degner
Dec 12, 2013·Expert Review of Clinical Pharmacology·Enrico CocchiAlessandro Serretti
Sep 7, 2018·American Journal of Therapeutics·Ainhoa Gómez-LumbrerasCristina Aguilera
Jan 6, 2021·Archives of Toxicology·Nevena Todorović VukotićSnežana B Pajović
Oct 27, 2021·Human Psychopharmacology·David S Baldwin
Dec 3, 2011·General Hospital Psychiatry·Karim SedkySteven Lippmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

International Journal of Psychiatry in Medicine
Francisca Llinares TelloJuan Pablo Ordovás Baines
Journal of Clinical Psychopharmacology
M HummerW W Fleischhacker
Progress in Neuro-psychopharmacology & Biological Psychiatry
Laurence Mouradian-StamatiadisWanda Cabaret
© 2022 Meta ULC. All rights reserved